Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Samuel R. Denmeade, Blair Egerdie, Gary Steinhoff, Rosemina Merchant, Ralph Abi-Habib, Peter Pommerville

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia'. Together they form a unique fingerprint.

Medicine & Life Sciences